Subscription Required

Only paid subscribers* to Specialty Pharmacy News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Specialty Pharmacy News receive

  • 12 monthly issues packed with news and strategies on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest grouped for convenient reading
    • Bonus reports for subscribers, and
    • Regular postings from your editor.
View a sample and get more information
November 2017

Recent Stories

From Specialty Pharmacy News - As the nascent United States biosimilars industry continues to gain footing, some policies also have adjusted to fit the market. One of those will go into effect Jan. 1, impacting Medicare Part B. Per the Medicare Physician Fee Schedule (PFS) for calendar year (CY) 2018 (82 Fed. Reg 52976, Nov. 15, 2017), CMS will give each biosimilar its own Healthcare Common Procedure Coding System (HCPCS) code. Read more

Although there has been no shortage of PBMs buying specialty pharmacies, the… Read more

With a booming pipeline of specialty drugs that fall under the medical… Read more

Hemophilia is a unique condition that’s unlike many therapeutic categories treated with… Read more

From the Editor

Welcome to your Specialty Pharmacy News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with your comments on the last issue of Specialty Pharmacy News, story ideas for future issues, or any other suggestions you have that can make the newsletter more useful for you.

November 16, 2017
FDA Begins Implementing Naming Guidance

The FDA has started adding 4-letter suffixes to non-biosimilar biologics per its January final guidance: Mepsevii (vestronidase alfa-vjbk) and Hemlibra (emicizumab-kxwh)

August 30, 2017
First Gene Therapy Gets FDA Approval

FDA approves first gene therapy in U.S., Novartis’ CAR-T drug Kymriah, for treatment of people up to 25 years old with B-cell precursor acute lymphoblastic leukemia that is refractory or has relapsed at least twice

August 2, 2017
CMS Unveils 2018 Standard Control Formulary

CMS will remove 17 drugs across 10 classes from its Standard Control Formulary in 2018, will launch Transform Value program in oncology, obesity, respiratory areas

It's quick and easy to sign up for FREE access to!

Why do I need to register?